NEW DELHI, Dec 8 - Three COVID-19 vaccine candidates, developed by Bharat Biotech, Serum Institute of India and Pfizer, are under active consideration of India�s drug regulator and there is hope that early licensure is possible for all or any of them, the Union Health Ministry said on Tuesday.
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for their potential COVID-19 vaccines.
At a press briefing, NITI Aayog member (Health) VK Paul said the COVID-19 situation in India has stabilised with active cases showing a �clear-cut declining trend� even though the pandemic situation in many other countries is becoming quite serious.
Asked what steps would be followed by the DCGI in the absence of a water-tight emergency use authorisation law for granting licence to vaccine makers, Union Health Secretary Rajesh Bhushan said not all countries� regulatory framework or rules and acts mention emergency use authorisation. � PTI